Niagen Bioscience, Inc. — Director's Dealing 2018

Dec 12, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-11-08

Reporting Person: Roberts Matthew A (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (right to buy)	$2.85	2026-10-18	Common Stock (10000)		Direct

Footnotes

F1: Options vested in a series of 24 equal monthly installments from the grant date of October 18, 2016